Clinical Case 2/2 –

BioDelivery Sciences to Present at the 25th Annual Piper Jaffray Healthcare …
Additionally, Dr. Sirgo will provide an update on the progress made by BDSI and its commercial partner, Endo Health Solutions, with the ongoing Phase 3 clinical program for BEMA Buprenorphine for the treatment of chronic pain along with updated plans …
Read more on Sacramento Bee

BioDelivery Sciences gets good news from FDA
The company also expects to have results from its initial Phase 3 clinical trial of BEMA Buprenorphine, the company's experimental treatment for chronic pain, by early next year. BioDelivery shares closed Monday at $ 4.95, up 15 cents. The stock is up …
Read more on News & Observer

Related Buprenorphine Treatment Information…

Comments are closed.